Eftilagimod Alfa is a fusion protein commercialized by Immutep, with a leading Phase II program in Non-Small Cell Lung Carcinoma. According to Globaldata, it is involved in 24 clinical trials, of which 11 were completed, 4 are ongoing, 6 are planned, and 3 were terminated. GlobalData uses proprietary data and analytics to provide a complete picture of Eftilagimod Alfa’s valuation in its risk-adjusted NPV model (rNPV). Buy the model here.
The revenue for Eftilagimod Alfa is expected to reach an annual total of $433 mn by 2035 globally based off GlobalData’s Expiry Model. The drug’s revenue forecasts along with estimated costs are used to measure the value of an investment opportunity in that drug, otherwise known as net present value (NPV). Applying the drug’s phase transition success rate to remaining R&D costs and likelihood of approval (LoA) to sales related costs provides a risk-adjusted NPV model (rNPV). The rNPV model is a more conservative valuation measure that accounts for the risk of a drug in clinical development failing to progress.
Eftilagimod Alfa Overview
eftilagimod alfa (IMP-321, EDP-202) is under development for the treatment of HER2-negative hormone receptor-positive metastatic breast cancer, soft tissue sarcoma, peritoneal cancer, triple-negative breast cancer, non-small cell lung cancer, recurrent head and neck cancer squamous cell carcinoma, as an adjuvant therapy for metastatic melanoma, hepatocellular carcinoma, metastatic urothelial cancer and solid tumors. It is administered through subcutaneous, intratumoral and intraperitoneal routes. It is a recombinant soluble human lymphocyte-activation gene 3 (LAG-3) IgG Fc fusion protein. The drug candidate is developed by using ImmuFact technology.
The drug candidate was also under development for hepatitis B, pancreatic adenocarcinoma, unspecified influenza virus infection, metastatic renal cell carcinoma, coronavirus disease 2019 and prostate cancer.
Immutep is a developer of immunotherapeutic products for the treatment of cancer and autoimmune diseases. The company provides products based on the LAG-3 immune control mechanism which is active in the regulation of the T cell immune response. It develops IMP761, a humanized monoclonal antibody that binds to LAG-3 and autoreactive T-cells as an agonist to reduce immune reactions in autoimmune diseases, and others. Immutep’s IMP321 is in clinical development for the treatment of a range of cancer indications. The company collaborates with pharmaceutical and biotech companies for research and development activities. It has operations in Australia, Germany and France. Immutep is headquartered in Sydney, New South Wales, Australia.
The company reported revenues of (Australian Dollars) AUD0.5 million for the fiscal year ended June 2022 (FY2022), an increase of 14.6% over FY2021. The operating loss of the company was AUD33.9 million in FY2022, compared to an operating loss of AUD20.7 million in FY2021. The net loss of the company was AUD32.2 million in FY2022, compared to a net loss of AUD29.9 million in FY2021.
For a complete picture of Eftilagimod Alfa’s valuation, buy the drug’s risk-adjusted NPV model (rNPV) here.